Spyre Therapeutics, Inc.
SYRENasdaq
$100.23
↑ +6.5%Jul 17 close · end-of-day
Price
1Y↑ +518.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$179.4M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-26.8%
ROIC
—
Debt / Equity
—
Net Cash
$741.5M
Return 1Y
+493.4%
Company profile
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
- CEO
- Cameron Turtle
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 73
- Headquarters
- Massachusetts
- Website
- spyre.com
Management & directors
- Burrows Scott LChief Financial Officer
- Sloan SheldonChief Medical Officer
- Turtle CameronChief Executive Officer
Roles derived from SEC Form 4 filings.
Earnings
SYRE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.74—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $18.7M | $2.3M | $886,000.00 | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$81.5M | -$65.6M | -$84.8M | -$242.3M | -$208.6M | -$209.6M |
| Net income | -$80.9M | -$65.8M | -$83.8M | -$338.8M | -$208.0M | -$155.2M |
| Diluted EPS | -$1.52 | -$25.02 | -$24.86 | $13.76 | — | — |
| Operating cash flow | -$75.8M | -$53.7M | -$80.1M | -$99.9M | -$157.4M | -$169.3M |
| Free cash flow | -$80.1M | -$54.3M | -$80.2M | -$99.9M | -$157.4M | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -350.3% | -3640.2% | -27348.0% | — | — |
| Net margin | — | -351.1% | -3598.8% | -38238.1% | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$44.1M | -$55.4M | -$61.3M | -$53.6M | -$41.9M | -$56.9M | -$57.2M | -$45.6M |
| Net income | -$38.8M | -$69.0M | -$56.3M | -$44.8M | -$36.7M | -$11.2M | -$62.5M | -$69.0M |
| Diluted EPS | $0.59 | $1.06 | — | — | — | -$0.15 | — | -$0.74 |
| Operating cash flow | -$62.2M | -$29.4M | -$37.2M | -$41.0M | -$46.6M | -$37.1M | -$44.6M | -$57.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jun 24, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Turtle Cameron· Chief Executive Officer | Sale | 10,176 | $87.44 | $889,789.44 | filing |
| 2026-07-01 | Sloan Sheldon· Chief Medical Officer | Sale | 6,500 | $87.52 | $568,880.00 | filing |
| 2026-07-01 | Burrows Scott L· Chief Financial Officer | Sale | 5,775 | $87.55 | $505,601.25 | filing |
| 2026-07-01 | Turtle Cameron· Chief Executive Officer | Sale | 4,234 | $88.12 | $373,100.08 | filing |
| 2026-07-01 | Sloan Sheldon· Chief Medical Officer | Option exercise | 8,334 | $27.46 | $228,851.64 | filing |
| 2026-07-01 | Sloan Sheldon· Chief Medical Officer | Sale | 1,834 | $88.34 | $162,015.56 | filing |
| 2026-07-01 | Burrows Scott L· Chief Financial Officer | Sale | 1,725 | $88.37 | $152,438.25 | filing |
| 2026-07-01 | Burrows Scott L· Chief Financial Officer | Option exercise | 7,500 | $14.50 | $108,750.00 | filing |
| 2026-07-01 | Turtle Cameron· Chief Executive Officer | Sale | 590 | $88.91 | $52,456.90 | filing |
| 2026-06-25 | Burrows Scott L· Chief Financial Officer | Sale | 10,000 | $87.14 | $871,400.00 | filing |
| 2026-06-25 | Burrows Scott L· Chief Financial Officer | Sale | 5,000 | $87.12 | $435,600.00 | filing |
| 2026-06-25 | Burrows Scott L· Chief Financial Officer | Option exercise | 15,000 | $14.50 | $217,500.00 | filing |
| 2026-06-23 | Fairmount Funds Management LLC | Sale | 4,684,781 | $85.31 | $399.7M | filing |
| 2026-06-23 | Fairmount Funds Management LLC | C | 666,680 | — | — | filing |
| 2026-06-22 | HENDERSON MICHAEL THOMAS | Sale | 20,000 | $100.00 | $2.0M | filing |
| 2026-06-03 | Sloan Sheldon· Chief Medical Officer | Sale | 8,333 | $75.00 | $624,975.00 | filing |
| 2026-06-03 | Sloan Sheldon· Chief Medical Officer | Option exercise | 8,333 | $27.46 | $228,824.18 | filing |
| 2026-06-01 | Turtle Cameron· Chief Executive Officer | Sale | 8,149 | $70.50 | $574,504.50 | filing |
| 2026-06-01 | Turtle Cameron· Chief Executive Officer | Sale | 3,557 | $69.40 | $246,855.80 | filing |
| 2026-06-01 | Turtle Cameron· Chief Executive Officer | Sale | 3,294 | $71.38 | $235,125.72 | filing |
| 2026-06-01 | Burrows Scott L· Chief Financial Officer | Sale | 3,100 | $72.06 | $223,386.00 | filing |
| 2026-06-01 | Burrows Scott L· Chief Financial Officer | Sale | 2,599 | $70.77 | $183,931.23 | filing |
| 2026-06-01 | Burrows Scott L· Chief Financial Officer | Sale | 1,801 | $69.75 | $125,619.75 | filing |
| 2026-06-01 | Burrows Scott L· Chief Financial Officer | Option exercise | 7,500 | $14.50 | $108,750.00 | filing |
| 2026-05-08 | HENDERSON MICHAEL THOMAS | Sale | 33,513 | $73.72 | $2.5M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.